Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Immunogenicity Data Drove Monkeypox Dose-Sparring Decision…It Also Drove Initial Approval

Executive Summary

Comfort with the initial approval based on inferred effectiveness may have made the current EUA process more palatable to US FDA officials but means there is a bigger gap in what’s known about the vaccine’s effectiveness overall.

You may also be interested in...

EU, UK & Brazil Take Steps To Boost Access To Monkeypox Vaccines

Regulators in the EU and the UK are exploring the intradermal use of monkeypox vaccine as a dose-sparing measure to stretch out scarce supplies, while Brazil is to waive the registration requirements for imported vaccines and therapeutics for monkeypox.

US NIH Testing Strategy To Stretch Monkeypox Vaccine Supply Even Further

The National Institutes of Health is gearing up to launch a trial that would test a smaller intradermal dose of Jynneos than was recently given an emergency use authorization, which could double vaccine supplies relative to currently available intradermal dosing. The trial still will leave the efficacy question unanswered. 

US Encouraging Monkeypox Vaccine Maker To Work With Large Pharma To Up Supply

The US FDA's Peter Marks also says the intradermal dose-sparing plan was motivated by concern over city and state one-dose strategies. 

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts